Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 18/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 18/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 17/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5880749 | 1.00 | OPRM1 (0.40) | OPRM1OPRK1OPRD1DRD2DRD3 | |
| SCHEMBL5880816 | 1.00 | OPRM1 (0.40) | OPRM1OPRK1OPRD1DRD2DRD3 | |
| SCHEMBL3987928 | 0.89 | CYP4F2 (0.30) | — | |
| SCHEMBL5880854 | 0.86 | ALDH1A1 (0.38) | — | |
| SCHEMBL3986253 | 0.86 | TAAR1 (0.38) | — | |
| SCHEMBL3986868 | 0.86 | SMN1; SMN2 (0.34) | — | |
| SCHEMBL5880732 | 0.86 | RAB9A (0.33) | OPRM1OPRK1OPRD1 | |
| SCHEMBL5880848 | 0.86 | GAA (0.34) | — | |
| SCHEMBL5880880 | 0.85 | EPHX1 (0.39) | — | |
| SCHEMBL5880858 | 0.85 | RAB9A (0.35) | OPRM1OPRK1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115658-B2 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase | AGOURON PHARMACEUTICALS, INC. (US) | 2006-10-03 | — | — | US | disclosed |
| US-20040023958-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. | 2004-02-05 | — | — | US | disclosed |
| WO-2003095441-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023958-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | POLRMT, RNGTT, RNASE1 | OPRM1 1930/4885OPRK1 1942/4885OPRD1 1937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.